Author + information
- Received April 24, 2018
- Accepted April 26, 2018
- Published online August 20, 2018.
- Vivek Y. Reddy, MDa,b,∗ (, )
- Jacob Koruth, MDa,
- Pierre Jais, MDc,
- Jan Petru, MDb,
- Ferdinand Timko, MDd,
- Ivo Skalsky, MDd,
- Robert Hebeler, MDe,
- Louis Labrousse, MDf,
- Laurent Barandon, MDf,
- Stepan Kralovecb,
- Moritoshi Funosako, MDb,
- Boochi Babu Mannuva, MDb,
- Lucie Sediva, MDb and
- Petr Neuzil, MD, PhDb
- aDepartment of Electrophysiology, Division of Cardiology, Icahn School of Medicine at Mount Sinai, New York, New York
- bDepartment of Cardiology, Homolka Hospital, Prague, Czech Republic
- cDepartment of Cardiology, Division of Electrophysiology, IHU LIRYC ANR-10-IAHU-04, University of Bordeaux, CHU Bordeaux, Bordeaux, France
- dDepartment of Cardiac Surgery, Homolka Hospital, Prague, Czech Republic
- eDepartment of Cardiothoracic Surgery, Baylor Medical Center, Dallas, Texas
- fMedico-Surgical Service of Valvulopathies and Cardiomyopathies - Adult Cardiac Surgery, IHU LIRYC ANR-10-1AHU-04, University of Bordeaux, CHU Bordeaux, Bordeaux, France
- ↵∗Address for correspondence:
Dr. Vivek Y. Reddy, Helmsley Electrophysiology Center, Icahn School of Medicine at Mount Sinai, One Gustave L. Levy Place, P.O. Box 1030, New York, New York 10029.
Objectives The authors report the first acute clinical experience of atrial fibrillation ablation with PEF—both epicardial box lesions during cardiac surgery, and catheter-based PV isolation.
Background Standard energy sources rely on time-dependent conductive heating/cooling and ablate all tissue types indiscriminately. Pulsed electric field (PEF) energy ablates nonthermally by creating nanoscale pores in cell membranes. Potential advantages for atrial fibrillation ablation include: 1) cardiomyocytes have among the lowest sensitivity of any tissue to PEF—allowing tissue selectivity, thereby minimizing ablation of nontarget collateral tissue; 2) PEF is delivered rapidly over a few seconds; and 3) the absence of coagulative necrosis obviates the risk of pulmonary vein (PV) stenosis.
Methods PEF ablation was performed using a custom over-the-wire endocardial catheter for percutaneous transseptal PV isolation, and a linear catheter for encircling the PVs and posterior left atrium during concomitant cardiac surgery. Endocardial voltage maps were created pre- and post-ablation. Continuous and categorical data are summarized and presented as mean ± SD and frequencies.
Results At 2 centers, 22 patients underwent ablation under general anesthesia: 15 endocardial and 7 epicardial. Catheter PV isolation was successful in all 57 PVs in 15 patients (100%) using 3.26 ± 0.5 lesions/PV: procedure time 67 ± 10.5 min, catheter time (PEF catheter entry to exit) 19 ± 2.5 min, total PEF energy delivery time <60 s/patient, and fluoroscopy time 12 ± 4.0 min. Surgical box lesions were successful in 6 of 7 patients (86%) using 2 lesions/patient. The catheter time for epicardial ablation was 50.7 ± 19.5 min. There were no complications.
Conclusions These data usher in a new era of tissue-specific, ultrarapid ablation of atrial fibrillation.
These clinical trials were supported by the manufacturer of the ablation catheters, Iowa Approach Inc. Drs. Reddy and Jais have served as a consultant for Biosense Webster, Boston Scientific, and Iowa Approach; have received grant support from Biosense Webster and Boston Scientific; and have stock options in Iowa Approach. Dr. Koruth has served as a consultant for Biosense Webster and Iowa Approach. Drs. Petru, Kralovec, Sediva, and Neuzil were supported by a scientific grant from the Ministry of Health, Czech Republic (NHH 00023884). Dr. Hebeler has served as a consultant for and has stock options in Iowa Approach. Dr. Neuzil has served as a consultant for and received grant support from Biosense Webster and Boston Scientific; and has received scientific grant support from Iowa Approach. All other authors have reported that they have no relationships relevant to the contents of this paper to disclose.
All authors attest they are in compliance with human studies committees and animal welfare regulations of the authors’ institutions and Food and Drug Administration guidelines, including patient consent where appropriate. For more information, visit the JACC: Clinical Electrophysiology author instructions page.
- Received April 24, 2018.
- Accepted April 26, 2018.
- 2018 American College of Cardiology Foundation
This article requires a subscription or purchase to view the full text. If you are a subscriber or member, click Login or the Subscribe link (top menu above) to access this article.